Lovenox Allows Home Treatment of Acute DVT

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 3
Volume 8
Issue 3

COLLEGEVILLE, Penn-Lovenox (enoxaparin sodium) Injection, from Rhône-Poulenc Rorer Inc., has received FDA approval for the inpatient treatment of acute deep-vein thrombosis (DVT) with or without pulmonary embolism and the outpatient treatment of acute DVT without pulmonary embolism. Both indications require that Lovenox be administered in conjunction with warfarin sodium.

COLLEGEVILLE, Penn—Lovenox (enoxaparin sodium) Injection, from Rhône-Poulenc Rorer Inc., has received FDA approval for the inpatient treatment of acute deep-vein thrombosis (DVT) with or without pulmonary embolism and the outpatient treatment of acute DVT without pulmonary embolism. Both indications require that Lovenox be administered in conjunction with warfarin sodium.

Cancer surgery and chemotherapy are risk factors for DVT, the company said. Until now, the standard treatment has been unfractionated heparin, administered through continuous IV infusion and requiring hospitalization for several days.

Now, the company said, patients diagnosed with DVT can be treated in the hospital or in their own homes via twice-daily subcutaneous injections of Lovenox. A study at Kaiser Permanente Medical Center, Fontana, Calif, showed an estimated cost savings of $547 per patient with home use of Lovenox.

Lovenox, a low-molecular-weight heparin, was initially approved in 1993 for prevention of DVT in hip and knee replacement surgery and high-risk abdominal surgery.

Recent Videos
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Related Content